JP2025504543A5 - - Google Patents
Info
- Publication number
- JP2025504543A5 JP2025504543A5 JP2024544441A JP2024544441A JP2025504543A5 JP 2025504543 A5 JP2025504543 A5 JP 2025504543A5 JP 2024544441 A JP2024544441 A JP 2024544441A JP 2024544441 A JP2024544441 A JP 2024544441A JP 2025504543 A5 JP2025504543 A5 JP 2025504543A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- monoclonal antibody
- antigen
- seq
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/075109 | 2022-01-29 | ||
| CN2022075109 | 2022-01-29 | ||
| PCT/CN2023/073699 WO2023143564A1 (en) | 2022-01-29 | 2023-01-29 | Antibody against btla and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504543A JP2025504543A (ja) | 2025-02-12 |
| JP2025504543A5 true JP2025504543A5 (https=) | 2025-10-17 |
Family
ID=87470720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544441A Pending JP2025504543A (ja) | 2022-01-29 | 2023-01-29 | Ｂｔｌａに対する抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250388673A1 (https=) |
| EP (1) | EP4469482A4 (https=) |
| JP (1) | JP2025504543A (https=) |
| KR (1) | KR20240139083A (https=) |
| CN (1) | CN118871465A (https=) |
| AR (1) | AR128377A1 (https=) |
| AU (1) | AU2023212896A1 (https=) |
| CA (1) | CA3250219A1 (https=) |
| IL (1) | IL314579A (https=) |
| MX (1) | MX2024009309A (https=) |
| TW (1) | TW202340253A (https=) |
| WO (1) | WO2023143564A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2097447A4 (en) * | 2006-11-15 | 2010-12-29 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE |
| BR112012007875A2 (pt) * | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| MX2018010295A (es) * | 2016-02-26 | 2019-06-06 | Inst Nat Sante Rech Med | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. |
| CN110790837A (zh) * | 2018-08-02 | 2020-02-14 | 上海君实生物医药科技股份有限公司 | 抗btla抗体 |
-
2023
- 2023-01-29 CN CN202380023757.XA patent/CN118871465A/zh active Pending
- 2023-01-29 CA CA3250219A patent/CA3250219A1/en active Pending
- 2023-01-29 AU AU2023212896A patent/AU2023212896A1/en active Pending
- 2023-01-29 WO PCT/CN2023/073699 patent/WO2023143564A1/en not_active Ceased
- 2023-01-29 KR KR1020247029189A patent/KR20240139083A/ko active Pending
- 2023-01-29 IL IL314579A patent/IL314579A/en unknown
- 2023-01-29 US US18/833,730 patent/US20250388673A1/en active Pending
- 2023-01-29 JP JP2024544441A patent/JP2025504543A/ja active Pending
- 2023-01-29 EP EP23746441.7A patent/EP4469482A4/en active Pending
- 2023-01-29 MX MX2024009309A patent/MX2024009309A/es unknown
- 2023-01-30 AR ARP230100205A patent/AR128377A1/es unknown
- 2023-01-30 TW TW112103090A patent/TW202340253A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230279117A1 (en) | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics | |
| US11845795B2 (en) | NKp46 binding proteins | |
| JP6932693B2 (ja) | カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用 | |
| AU2008304778B9 (en) | Method of modifying isoelectric point of antibody via amino acid substitution in CDR | |
| US20200377594A1 (en) | Humanized antibodies for cd3 | |
| US12076413B2 (en) | Compositions and methods for modulating delta gamma chain mediated immunity | |
| RU2015152084A (ru) | Гетеромультимеры с уменьшенной или подавленной эффекторной функцией | |
| JP6223966B2 (ja) | エフェクター機能を有する抗ｃｘｃｒ４抗体および癌治療のためのその使用 | |
| RU2012122203A (ru) | Композиции и способы для лечения восполительных нарушений | |
| IL256997A (en) | Anti-cd154 antibodies and methods of using them | |
| JP2013509158A5 (https=) | ||
| KR20210057752A (ko) | 항-cd38 항체, 이의 항원 결합 단편, 및 제약 용도 | |
| TW202509068A (zh) | 結合ox40l之抗體及使用方法 | |
| US20230235058A1 (en) | Btla antibodies | |
| WO2025171006A1 (en) | Il-23 binding protein compositions and methods of use | |
| JP2025504543A5 (https=) | ||
| WO2025111585A1 (en) | Engineered bispecific molecules and methods of use | |
| EP4396227B1 (en) | Improved fc silenced anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity | |
| US20250304684A1 (en) | Engineered bispecific molecules and methods of use | |
| WO2025170982A2 (en) | Il-23 antibody compositions and methods of use | |
| WO2026090071A1 (en) | Cd19/cd38 multispecific antibodies for autoimmune and inflammatory therapies | |
| WO2025035124A1 (en) | Engineered bispecific molecules and methods of use | |
| CN121399160A (zh) | 靶向ccr2的抗体 | |
| WO2026050274A2 (en) | April binding proteins, compositions, and methods of use thereof | |
| WO2026064545A1 (en) | Engineered tl1a targeting regions and methods of use |